Search Results
Results found for "Inversago Pharma"
- Pepducin-mediated G Protein-Coupled Receptor Signaling in the Cardiovascular System
Over the past 2 decades, pepducins have progressed initially from pharmacologic tools used to manipulate
- G protein-biased GPR3 signaling ameliorates amyloid pathology in a preclinical Alzheimer's disease..
provide proof of concept for the development of safer GPCR-targeting therapeutics with more directed pharmacological
- Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors
Here, we review how nanobodies have been adopted to elucidate the structure, pharmacology, and signaling
- Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent GPCR...
Finally, we validated A2BAR as a potential pharmacological tool in CRC, using selective antagonists,
- Use of CRISPR/Cas9-edited HEK293 cells reveals that both conventional and novel protein kinase C...
Our PKC KO cell lines expand the repertoire of KO HEK293A cell lines available to research GPCR pharmacology Moreover, since pharmacological tools to study PKC isozymes generally lack specificity and/or potency
- Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL/6J mice
Much of the understanding of psychedelic pharmacology is derived from rodent models, but most of this However, the pharmacokinetic properties of DOI differed among sexes - brain and plasma concentrations Together, these results suggest strain-dependent and sex-related differences in the behavioral and pharmacokinetic
- Adrenal G Protein-Coupled Receptors and the Failing Heart: A Long-distance, Yet Intimate Affair
Despite considerable advances in pharmacological treatment, HF represents a severe clinical and social effects of angiotensin II (AngII) and aldosterone on the failing heart, are part of the mainstay HF pharmacotherapy
- GB83, an Agonist of PAR2 with a Unique Mechanism of Action Distinct from Trypsin and PAR2-AP
bona fide agonist of PAR2 that uniquely modulates PAR2-mediated cellular signaling and is a useful pharmacological
- Although the cannabinoid type-2 receptor (CB2) is highly expressed in the immune system, emerging...
The development of new CB2-related pharmacological and genetic tools, including the first small molecule
- GRK2 in cardiovascular disease and its potential as a therapeutic target
Despite major advances in the field of pharmacological CVD treatments, particularly in the field of heart Additionally, GPCR dysregulation underlies multiple models of cardiac pathology, and most pharmacological
- Synthesis and characterization of an orally bioavailable small molecule agonist of the apelin recept
bioavailable compound 47 with favorable agonist potency (Ca2+EC50 = 24 nM, cAMPi EC50 = 6.5 nM) and pharmacokinetic
- Fluorescent Ligands Targeting Intracellular Allosteric Binding Site of the Chemokine Receptor CCR2
small-molecule-based fluorescent CCR2 ligand 14 represents a promising tool for future studies of CCR2 pharmacology
- G protein-coupled receptor 21 in macrophages: An in vitro study
analyzing (i) its involvement in cell migration and cytokine release and (ii) the consequence of its pharmacological
- Molecular basis for ligand modulation of the cannabinoid CB 1 receptor
LINKED ARTICLES: This article is part of a themed issue on Structure Guided Pharmacology of Membrane
- In vitro assays for the functional characterization of (psychedelic) substances at the serotonin...
perception, and thought, and have the activation of serotonin (5-HT) 2A receptors (5-HT2A Rs) as a main pharmacological
- Opioid Ligands Addressing Unconventional Binding Sites and More Than One Opioid Receptor Subtype
develop drugs with less side effects, and tools to explore the ORs nature and function, various (poly)pharmacological
- GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma
Through genetic and pharmacologic modulations of GRK3, a series of functional and molecular studies were
- Delineation of GPR15 receptor-mediated Gα protein signaling profile in recombinant mammalian cell
Here, GPR15L(25-81) and GPR15L(71-81) are used as pharmacological tool compounds to delineate the GPR15
- To probe the activation mechanism of the Delta opioid receptor by an agonist ADL5859 started from...
inactive conformation using molecular dynamic simulations "The δ-opioid receptor (DOR) is a critical pharmaceutical
- Isoforms of GPR35 have distinct extracellular N-termini that allosterically modify...
The pharmacological profiles and mechanistic insights of our study provide clues for the future design
- A broad look into the future of systemic sclerosis
Pharmacological interventions, although for other indications, are already in clinical use to address
- Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5...
receptors (SSTs) are class A GPCRs abundantly expressed in pituitary tumors where they represent the main pharmacological
- Interacting binding insights and conformational consequences of the differential activity of...
major non-psychoactive phytocannabinoid present in the plant Cannabis sativa, has displayed beneficial pharmacological Our work will pave the way for understanding the CBD pharmacology at a molecular level and aid in harnessing
- GPCR kinase phosphorylation of distal C-tail sites specifies βarrestin1-mediated signaling by...
We demonstrate by pharmacologic inhibition of GRK2/3-mediated phosphorylation of the chemokine receptor
- Addex Raises $10 Million In Equity Financing
Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical
- Ermium Therapeutics has constituted its SAB
Therapeutics Announces the Formation of a Scientific Advisory Board comprising international leaders in GPCRs pharmacology
- Addex Therapeutics To Release Full-Year 2021 Financial Results And Host Conference Call On March 10
Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical
- Therapeutic validation of an orphan G protein-coupled receptor: The case of GPR84
of GPR84 and, in the absence of direct structural information, recent developments and use of GPR84 pharmacological
- Jan Steyaert Named 2022 Jacob and Louise Gabbay Award Winner
research in biomedical sciences with the mechanistic understanding of one of the biggest classes of pharmaceutical
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...
"Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical

